Published online before print August 19, 2004, doi: 10.1161/01.ATV.0000142812.03840.6f
© 2004 American Heart Association, Inc.
Brief Reviews |
Chemokines
Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease
From Kardiovaskuläre Molekularbiologie, Universitätsklinikum Aachen, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany.
Correspondence to Christian Weber Kardiovaskuläre Molekularbiologie, Universitätsklinikum Aachen, Rheinisch-Westfälische Technische Hochschule Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany. E-mail cweber{at}ukaachen.de
 |
Abstract |
|---|
 Top Abstract IntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
Understanding the increasingly complex role of chemokines in various manifestations of atherosclerotic vascular disease and the apparent redundancy in their expression requires improved concepts defining the specialization and cooperation of chemokines in regulating the recruitment of mononuclear cells to vascular lesions. In an attempt to elaborate such models, this review highlights recent insights into the functional role of chemokines in mediating distinct steps during the atherogenic recruitment of monocytes and T cells obtained in genetically deficient mice and in suitable models. A particular focus is placed on the contribution of platelet chemokines deposited on endothelium for monocyte arrest, on differences in the involvement of chemokines between recruitment to native lesions and to neointimal lesions after arterial injury, and on closely related functions of macrophage migration inhibitory factor, a cytokine with considerable structural homology to chemokines. As an evolving aspect of atherosclerotic vascular disease, a role of chemokines, foremost stromal cell-derived factor-1
, in the recruitment of mononuclear progenitors of vascular cells during neointimal hyperplasia, endothelial recovery, and angiogenesis is discussed. The functional diversity and pleiotropy of chemokines in and beyond mononuclear cell recruitment awaits further elucidation to enable therapeutic targeting of atherogenesis by context-specific blockade of nonoverlapping chemokine receptor pairs. The complex role of chemokines in the recruitment of mononuclear cells to vascular lesions strongly suggests their specialization and cooperation in the atherosclerotic disease process. This review highlights recent insights into the function of chemokines in mediating distinct steps during the recruitment of monocytes and T cells to native atherosclerotic and neointimal lesions.
Key Words: atherosclerosis • chemokines • leukocytes • receptors
|
Introduction |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
Inflammation has emerged as a crucial force driving the initiation and progression of atherosclerotic lesion formation.1 Hypercholesterolemia as the best-documented risk factor contributing to atherogenesis instigates early endothelial activation or dysfunction accompanied by the expression of adhesion molecules and chemokines, and thereby leads to early subintimal infiltration with mononuclear cells, the first morphological sign of inflammation in the arteries.2–4 The mononuclear cells found in the lesions comprise
80% monocyte-derived macrophages, which transform into foam cells characteristic for fatty-streak lesions, and 10% to 20% lymphocytes predominantly of the Th1 helper subtype of T memory cells.5 In addition, the presence of mast cells and of dendritic cells interacting with T cells has been convincingly revealed in atherosclerotic lesions.5,6 Recently, the recruitment of a blood-borne progenitor cell subpopulation eventually giving rise to neointimal smooth muscle cells (SMC) and endothelial cells (EC) has been directly demonstrated in various models of atherosclerosis.7,8 The nonrandom attraction of mononuclear cells to specific tissue targets is governed by sequential steps in the interaction with the vessel wall, namely rolling mediated by selectin-carbohydrate interactions, integrin-dependent arrest, and transendothelial diapedesis triggered by chemokines. The refinement of this multistep model has revealed that these functions are to some degree mutually overlapping.9 For instance, integrins can mediate rolling interactions, whereas selectin interactions can serve as a prerequisite for transmigration, and some chemokines, such as fractalkine, can mediate arrest independent of and possibly before integrin interactions. The immobilization of chemokines to endothelial surface proteoglycans appears crucial for the efficacy of their arrest function and has also been implicated in the migratory response under shear flow (chemorheotaxis). This review discusses the role of chemokines in mononuclear cell recruitment to native atherosclerotic lesions and distinctive differences in their contribution to neointimal recruitment after vascular injury.
|
Chemokine Expression in Atherosclerotic Lesions |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
Chemokines constitute a family of structurally related and secretable basic chemotactic cytokines, which are classified in subgroups (CC, CXC, C, CXXXC) according to the position of the N-terminal cysteines. As the first and prototypic CC chemokine, MCP-1 (CCL2) has been detected in human atherosclerotic lesions and is induced primarily in medial and neointimal SMC as well as in monocytes/macrophages in animal models of atherosclerosis with dietary-induced hypercholesterolemia and after acute vascular injury.10–13 The CC chemokines TARC (CCL17), PARC (CCL18), and MDC (CCL22) have been identified in macrophage-rich areas of atherosclerotic lesions,14–16 whereas ELC (CCL19) expression has been detected in both SMC and monocyte-derived macrophages of human plaques.16 Also, the presence of the typically T cell-derived CC chemokines MIP-1
(CCL3), MIP-1ß (CCL4), RANTES (CCL5), and I-309 (CCL1) could be demonstrated in atherosclerotic plaques.17–19 A novel pathway of vascular inflammation has also been suggested by identifying the overexpression of eotaxin and its receptor CCR3 in atherosclerotic lesions.20 However, CXC chemokines with (IL-8/CXCL8, GRO-/CXCL1) or without ELR motif (Mig/CXCL9, IP10/CXCL10, I-TAC/CXCL11, SDF-1/CXCL12) and the transmembrane chemokines CXCL16 and fractalkine (CX3CL1) are detectable in atherosclerotic lesions.16,21–28 The expression, cellular localization, and target cells of chemokines in atherosclerotic plaques, their abbreviations, and functional involvement in mouse models of atherosclerosis or arterial injury are summarized in Tables 1 and 2 
. These data emphasize the variety and abundance of chemokines expressed in atherosclerotic lesions.
|
|
|
Genetic Deletion of Chemokines and Their Receptors in Murine Atherosclerosis Models |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
Given the pivotal role of monocytes in the process of lesion formation, it was not surprising that the direct evidence for the critical function of chemokines in atherogenesis came from the genetic deletion of the CC chemokine MCP-1 or its receptor CCR2, which mediate the attraction of monocytes but not neutrophils. The absence of MCP-1 or CCR2 in an atherogenic, ie, either low-density lipoprotein receptor-deficient (LDLR–/–) or apolipoprotein E-deficient (apoE–/–), background protects mice from the development of atherosclerotic lesions.29–31 The fact that MCP-1 was the first chemokine shown to play a pivotal role in atherogenesis likely reflects the fact that MCP-1–/– mice are viable and that effects of MCP-1 are mediated through a single receptor, CCR2. Transplantation of apoE3-Leiden mice with bone marrow deficient in CCR2 confirmed the role of CCR2 expressed on monocytes.32 Conversely, mice deficient in KC and CXCR2 are not viable or extremely susceptible to infection, respectively. As an alternative to genetic recombination, the repopulation of atherosclerosis-prone LDLR–/– mice with bone marrow deficiency in CXCR2, the receptor for the neutrophil chemokines IL-8 and GRO-
, resulted in a substantial reduction of atherosclerosis.33 Because neutrophils are not present in atherosclerotic lesions, this study implied an involvement of CXCR2 in the atherogenic recruitment of monocytes or other bone marrow-derived cells. CXCR2 is expressed on monocytes,34,35 and the CXCR2 ligands IL-8 and GRO- have been shown to enhance adhesion of monocytes to matrix proteins or EC activated with modified lipoproteins, respectively.36,37 Moreover, these ELR CXC chemokines have been implicated in angiogenesis,38,39 and by promoting plaque neovascularization, this may provide an alternative explanation for the contribution of CXCR2 to atherosclerosis. More recently, the genetic deletion of CCR2 and/or CXCR3 has suggested nonredundant roles of these receptors in the formation of atherosclerotic lesions.40 Moreover, fractalkine is expressed in lesional EC and most robustly in SMC located directly beneath lesional macrophages, but not in macrophages themselves,25,26 and genetic deletion of its receptor CX3CR1 reduced macrophage infiltration and retarded lesion development in the aorta to convincingly implicate CX3CR1 in atherogenesis.25,41 Although the targeted disruption of the RANTES receptor CCR5 failed to protect from atherosclerotic lesion formation,42 data on a deletion of the other RANTES receptors CCR1 and CCR3 are not yet available. |
Functional Specialization of Chemokines in Atherogenic Monocyte and T Cell Recruitment |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
With the apparent redundancy of chemokine expression and function in atherosclerotic lesions in mind, it is not easily conceivable why a deletion of individual chemokines or their receptors would each lead to a marked reduction in lesion formation and is not compensated by other chemokine receptor pairs. This would indicate that MCP-1, IL-8, and fractalkine do not act independently, but rather in concert to efficiently recruit circulating monocytes into lesions, and further insinuates that a functional specialization of chemokines and their receptors at distinct steps of the atherogenic recruitment process exists to allow for nonredundant roles.
Previous evidence suggested that a hierarchical involvement of GRO- and MCP-1 orchestrates monocyte arrest versus transmigration on activated EC, respectively.43 Although a preferential immobilization of endogenous GRO- via endothelial heparan sulfate proteoglycans stipulated its functional specialization in arrest on activated endothelium, the MCP-1/CCR2 axis did not appear to be involved in triggering arrest but was well-suited to mediate subsequent transendothelial migration under flow conditions (Figure 1). This may reflect different patterns in the presentation or directional secretion of MCP-1.43 The concept that immobilization to specific proteoglycans may lead to a local enrichment of chemokines to achieve concentrations sufficient to trigger arrest is supported by findings that exogenous IL-8 and MCP-1 at high concentrations can induce firm arrest of monocytes on EC under physiological flow.44 Moreover, a simultaneous requirement of apically presented chemokines and shear flow for transendothelial migration has been demonstrated for certain chemokines and termed chemorheotaxis.45 Hence, the functional specialization of GRO and MCP-1 may reflect a specific coupling to distinct signaling pathways instrumental in mediating mechanisms either permissive to triggering arrest (eg, integrin clustering) or transmigration/chemorheotaxis. Importantly, this model establishing a division of labor for chemokines could be confirmed in a study on monocyte accumulation on early atherosclerotic endothelium in carotid arteries of apoE–/– mice.46,47 Here, KC and CXCR2 were able to capture monocytes in flow, whereas no evidence for an involvement of MCP-1 and CCR2 could be obtained.46 However, genetic deletion of CXCR2, MCP-1, or CCR229–33 or its inhibition by overexpression of a truncated MCP-1 peptide antagonist protected against atherosclerosis and monocyte infiltration,48 implying that MCP-1 but not GRO- mediates subsequent subintimal immigration of monocytes.
|
The expression of the CXCR3 ligands Mig, IP10, and I-TAC has been detected in atheroma-associated cells, including EC, as well as an expression of their receptor CXCR3 on lesional T cells.23 Although a direct involvement of CXCR3 ligands in atherogenesis and atherogenic recruitment of mononuclear cells has not yet been reported, their functional role in recruitment of T cells is strongly inferred by findings that CXCR3 mediates the rapid and shear-resistant arrest of effector T lymphocytes triggered by IP10 and Mig on stimulated EC.49 More recent clues for a specific contribution of CXCR3 to atherogenesis indicate a function in early T cell-driven lesion formation not overlapping with a more prominent role of CCR2 in advanced lesions40 (F. Mach, personal communication). Nonredundant roles of CCR2 and CXCR3 are also indicated by the more pronounced protection against overall lesion formation in CCR2–/– CXCR3–/– apoE–/– triple knockout as compared with apoE–/– mice or deletion of either receptor in apoE–/– mice alone40 (F. Mach, personal communication). Similarly, it is conceivable from in vitro studies that immobilized SDF-1 may participate in the recruitment of memory T cells on activated EC in flow,45,50 because it may occur in growing lesions.
Fractalkine as a structurally distinct chemokine fused to a transmembrane mucin stalk51 represents another candidate engaged in atherogenic leukocyte recruitment. Although the transmembrane protein acts as an efficient adhesion molecule capturing monocytes and T cells on activated endothelium under flow conditions by an integrin-independent mechanism,52,53 cleavage by specific metalloproteases, such as ADAM17, of the mucin stalk can produce a soluble form of fractalkine with chemoattractant activity for these cells.54,55 Migration but not arrest induced by fractalkine, although both mediated through CX3CR1, is sensitive to pertussis toxin, supporting the concept that specialized functions in arrest and migration require distinct signal transduction pathways.51–53 Evidence for distinct modes of function depending on its form of presentation may further be derived from the intralesional localization of fractalkine. When expressed by lesional SMC, fractalkine may be prone to cleavage by metalloproteases into the promigratory soluble form, as insinuated by adjacent macrophage infiltrates.25 In contrast, transmembrane fractalkine on the endothelial surface may be less accessible to metalloproteases and thus predestined to mediate arrest of monocytes (Figure 1). Studies addressing the functions of fractalkine by using noncleavable and membrane-anchored mutants and overexpression of cleaving enzymes, eg, tumor necrosis factor-converting enzyme, are underway. Recently, a novel role for membrane-bound fractalkine has been described in platelet activation and adhesion,56 which may sustain recruitment mechanisms involving the delivery of platelet-derived chemokines as discussed.
As another transmembrane chemokine, CXCL16, which is expressed in dendritic cells, macrophages, and aortic SMC, has been detected in human and murine atherosclerotic lesions.27,28 CXCL16 has been shown to function as a scavenger receptor for oxidized LDL and can be upregulated in monocytes by interferon-
.27,28,57 Similar to fractalkine, CXCL16 acts as a chemoattractant and adhesion molecule for T cells and natural killer cells expressing its receptor CXCR6 without requiring signal transduction for integrin activation.58,59 The adhesive function of CXCL16 can be enhanced by blocking its shedding from the cell surface. Whereas constitutive shedding can be mediated by the metalloproteinase ADAM10, induced shedding, which is presumably more important in the lesion, involves ADAM17.57,60 By analogy, it may be postulated that the recruitment function of transmembrane and soluble CXCL16 for CXCR6-positive T cells resembles the role of fractalkine in monocyte/macrophage recruitment in native atherosclerotic lesions (Figure 1). The functional specialization of these chemokines in atherogenic recruitment summarized and depicted in Figure 1 puts the apparent redundancy into perspective and confers an enormous potential for selective, additive, and possibly synergistic modes of interference with this deleterious process.
|
Importance of Platelet Chemokines in Atherogenic Recruitment of Mononuclear Cells |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
Platelets represent another source of chemokines and their precursors, which may be involved in the process of atherogenic recruitment. From their
-granules, platelets secrete not only CXC chemokines, such as PF4 (CXCL4) or ENA-78, and precursors for the CXCR2 ligand NAP-2 (CXCL7), such as CTAP-III or ß-thromboglobulin, but also CC chemokines, such as MIP-1ß or RANTES.61 Initially, RANTES expression has been detected in macrophages of human atherosclerotic plaques and arteries with transplant atherosclerosis, and has been implicated in allograft rejection.17,18,62 Recently, the presence of RANTES has been revealed on the luminal surface of carotid arteries with early atherosclerotic endothelium or on neointimal lesions after arterial injury in apoE–/– mice.63 Subsequently, it could be demonstrated that activated platelets can deliver RANTES and PF4 to the endothelial lining of early atherosclerotic and neointimal lesions (Figure 1), as well as to the surface of monocytes via a mechanism involving platelet P-selectin.64,65 The deposition and immobilization of platelet-derived RANTES has been shown to trigger enhanced recruitment of monocytes on activated aortic endothelium but not on surface-adherent platelets.63,64 This may be related to the fact that platelets can also secrete the proteoglycan chondroitin sulfate, which can block the presentation and arrest function of RANTES on cell surfaces, eg, on platelets.66 Notably, a blockade of RANTES with the Met-RANTES receptor antagonist inhibited not only RANTES-mediated arrest in vitro but also neointimal macrophage infiltration and hyperplasia after arterial injury in hyperlipidemic mice.64 The important observation that the intermittent injection of activated, but not P-selectin-deficient, platelets exacerbated lesion formation in apoE–/– mice strongly suggests that mechanisms of P-selectin-mediated chemokine delivery are also relevant to the in vivo pathogenesis of native atherosclerosis.65 The concept that the deposition of RANTES may be an important mechanism underlying the involvement of platelets in native lesion formation is corroborated by findings that the long-term treatment with Met-RANTES reduced atherosclerotic lesion formation in apoE–/– mice.67 Alternatively, this could be explained by a blockade of RANTES produced in mononuclear cells infiltrating the lesions or by modulating other chemokine receptors, eg, by decreasing CCR2 mRNA.67 The hypothesis that beyond specific modes of chemokine presentation the functional specialization may be determined by the intrinsic characteristics of a given receptor has been further tested in a model in which RANTES immobilized on activated endothelium triggers the arrest of leukocytes.63,64 The use of selective receptor antagonists demonstrated that CCR1 but not CCR5 mediates RANTES-induced arrest of monocytes, activated T cells, and Th1 cells expressing different levels of CCR1 and CCR5. In contrast, CCR5 supported spreading along the endothelium, whereas both CCR1 and CCR5 contributed to transendothelial chemotaxis of these cells triggered by RANTES.68 This revealed that the engagement of different receptors by the same chemokine ligand can produce dramatically distinct functions, further extending the selectivity of specialization. In a study using RANTES mutants to define the structural features for its functions in leukocyte recruitment, oligomerization of RANTES was found to be crucial for CCR1-mediated arrest in flow, likely by bridging between surface-bound RANTES and CCR1, but not for CCR5-mediated transmigration.69 In contrast, proteoglycan binding of RANTES was essential for arrest and transmigration. The dichotomy of receptor-specific functions may rely on distinct structural prerequisites, ie, monomers sufficed for chemotaxis but not arrest.
Regarding a functional role of PF4 or ß-thromboglobulin secreted by platelets, little is known so far. Previous studies have shown a correlation of PF4 and thromboglobulin plasma levels as platelet activation markers and independent risk factors for carotid atherosclerosis, ie, wall thickness.70 Preliminary data indicate that ß-thromboglobulin, depending on its proteolytic conversion to NAP-2, can induce monocyte arrest when presented on activated endothelium, whereas PF4 secreted or deposited by activated platelets may synergistically enhance RANTES-triggered monocyte arrest (C. Weber et al, unpublished data, 2004). This may be caused by heterodimerization with RANTES, alterations of receptor specificity, or enhanced binding to proteoglycans. Alternatively, PF4 effects may be mediated via a spliced variant of CXCR3 described as a novel functional receptor.71 Beyond direct contributions to monocyte recruitment, chemokines such as SDF-1, MDC, or fractalkine have conversely been involved in platelet activation, which not only may cause aggregation and adhesion but also may sustain degranulation and deposition of platelet chemokines.24,56,72,73 Chemokine-mediated platelet activation, however, strongly depends on the presence of low levels of primary agonists such as ADP or thrombin.56,73 Thus, in comparison to stimulation with these mediators, platelet-activating chemokines rather appear to exert an adjuvant function in amplifying platelet activation and aggregation, or in promoting platelet function under inflammatory conditions.
|
Different Functions of MCP-1/CCR2 in Neointima Formation and Native Atherogenesis |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
Murine models of atherosclerosis have demonstrated the central role of the MCP-1/CCR2 axis in monocyte recruitment and lesion formation.29–31,48 In the context of hyperlipidemia, an induction of MCP-1 expression in SMC12 and an upregulation of CCR2 on monocytes74 have been described, which may account for the over-recruitment on monocytes into the vessel wall.13,75 In hyperlipidemic apoE–/– mice, wire-induced injury of the carotid artery caused a rapid upregulation of MCP-1 levels in serum and in the vessel wall, and MCP-1 staining was detectable in medial SMC but also in platelets adherent to the denuded vessel wall,76 and its inhibition diminished neointimal hyperplasia and macrophage infiltration.77,78 In vitro studies revealed that MCP-1 binds to the surface of adherent platelets and triggers monocyte arrest in flow.76 Hence, this pathway may be relevant for an excessive response to vascular injury. By contrast, a role of MCP-1/CCR2 in macrophage recruitment after arterial injury is less well-established in normolipidemia. Although monocyte accumulation was reduced after arterial cuff placement or stent placement,78,79 neointimal SMC content was decreased and macrophage content was unaffected in CCR2–/– mice or MCP-1 antibody-treated rats after endothelial denudation.80,81 Thus, the function of the MCP-1/CCR2 axis in vascular repair and monocyte recruitment appears to differ between normolipidemic and hyperlipidemic models.
Findings that surface-adherent platelets do not contain MCP-172 but show staining for MCP-1 after endothelial denudation, and that peak MCP-1 serum levels precede platelet coverage and maximum MCP-1 levels in the injured wall, imply that locally secreted MCP-1 is retained and presented by platelets adhering to the injury site.76 This is in accordance with a study reporting low-affinity binding of MCP-1 to platelets despite a lack of functional CCR2,82 extending evidence that endogenous chemokines can be concentrated on the surface of activated platelets,83 possibly via binding to proteoglycans.84 Beyond secretion and deposition of platelet-derived chemokines, this provides novel insights into a function of platelets in supporting chemokine-triggered monocyte recruitment.
Monocyte accumulation on early atherosclerotic endothelium in uninjured carotid arteries of apoE–/– mice exclusively relies on KC and CXCR2 but not on MCP-1 and CCR2, although both are expressed in the vessel wall.46 In contrast, blockade of MCP-1 profoundly inhibited monocyte arrest in denuded apoE–/– carotid arteries perfused ex vivo, with preserved monocyte arrest illustrated side-by-side in uninjured segments of the same artery (C. Weber et al, unpublished data, 2004). This suggests a differential and distinctive contribution of MCP-1 to monocyte arrest after endothelial denudation, which may require local concentration by binding to adherent platelets at the injury site (Figure 2). A causal relationship between early MCP-1-dependent monocyte arrest on denuded vessels and neointimal hyperplasia is inferred by reduced neointimal plaque area and macrophage content in hyperlipidemic apoE–/– mice with genetic deficiency in CCR2, whereas the relative content of neointimal SMC is expanded.76 This is in contrast to normolipidemic models of vascular injury in which neutralization of MCP-1 was associated with a decrease in neointimal SMC but not macrophage content.81,82 It could therefore be hypothesized that MCP-1 expression by medial SMC after endothelial denudation is aggravated in the context of hypercholesterolemia,12 so that sufficient concentrations may be achieved for immobilization on adherent platelets and triggering monocyte recruitment in denuded vessels. A neointimal expansion of SMC may in turn be attributable to a shift in the complex interplay of plaque chemokines toward activities for increasing SMC content as a hallmark of plaque stability, as discussed for SDF-17 or macrophage migration inhibitory factor (MIF).85
|
|
MIF as a Cytokine With Chemokine-Like Function Regulates Plaque Composition |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
It has recently been proposed to group mediators with similar functional patterns, which cannot be structurally classified into the known chemokine subfamilies, as a family termed chemokine-like function chemokines.86 Among other members, eg, leukotrienes or fMLP, known to signal via G-protein-coupled receptors, this group includes MIF, a pleiotropic inflammatory T cell and macrophage cytokine, which is involved in immune-mediated diseases, eg, septic shock and chronic inflammation.87,88 Although a membrane receptor for MIF is yet to be identified, MIF displays a remarkable homology in its 3-dimensional crystal structure with chemokines, in particular with a dimer of IL-889 and with MIP-3
,90 despite a lack of N-terminal cysteines. In support of a chemokine-like function, MIF has been found to desensitize the chemotactic activity of MCP-1 in monocytes and to stimulate cell migration.91,92 The pathogenic role of MIF in local tissue inflammation has been attributed to monocyte and T cell recruitment in a model of glomerulonephritis.93 An upregulation of MIF has been observed in EC, SMC, and macrophages during progression of atherosclerosis in humans94 and in hypercholesterolemic rabbits.95 Recent reports have helped to clarify the contribution of MIF to macrophage accumulation and its function in atherosclerotic disease. The role of MIF in neointimal lesion formation was studied after wire injury of carotid arteries in apoE–/– mice.85 MIF expression was upregulated in SMC early after endothelial denudation but predominantly found in EC and macrophage-derived foam cells at later stages. Neutralizing MIF markedly reduced neointimal macrophage content and inhibited transformation into foam cells. Conversely, the content of SMC and collagen in the neointima was increased, amounting to a slight reduction in neointimal area.85 This reflects a remarkable shift in the cellular composition of neointimal plaques toward a stabilized phenotype. In a study of arterial injury in LDLR–/– mice, blocking MIF inhibited neointimal hyperplasia and macrophage infiltration, as well as SMC proliferation, confirming an important role of MIF in plaque formation.96 The genetic deletion of MIF in LDLR–/– mice has also been shown to reduce lipid deposition and intimal thickening in the aorta.97 This retardation of native atherogenesis was accompanied by a decrease in lesional cell proliferation, protease expression, and activity. Although differences in these models may be caused by incomplete blockade by antibody treatment or related to the degree of injury, all data concur by establishing a novel pathway in unstable lesion formation by MIF.
In vitro flow assays revealed that a short-term incubation of aortic EC with MIF triggers monocyte arrest under flow conditions and that monocyte arrest induced by oxidized LDL is mediated by endothelial MIF.85 This observation supports a model in which MIF directly affects endothelial-monocyte interactions by a novel mechanism resembling the function of immobilized chemokines in native atherogenesis and after injury (Figures 1 and 2
). Preliminary data suggest that the induction of arrest is mediated via G-protein-coupled signaling possibly involving chemokine receptors (C. Weber et al, unpublished data, 2004). Thus, the contribution of MIF to atherogenesis may at least in part be caused by a chemokine-like function.
|
Crucial Role of SDF-1 in the Neointimal Recruitment of SMC Progenitor Cells
|
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
The CXC chemokine SDF-1
is essential for stem cell mobilization, bone marrow engraftment, and homing, as well as organ system vascularization.98–101 It is also expressed in human atherosclerotic plaques and effectively activates platelets in vitro.24 Because bone marrow-derived cells have been shown to contribute to neointimal SMC content in native atherosclerosis or after arterial injury,7,8,102 and because circulating SMC progenitors have been found in human blood, 103 this was highly suggestive of a participation of SDF-1 in human atherothrombotic disease and the response to vascular trauma. SDF-1 plasma levels were transiently elevated after wire injury of carotid arteries in apoE–/– mice,8 mediating a marked expansion of sca-1+ lineage– peripheral blood progenitor cells. The systemic injection of these cells after injury led to their SDF-1-dependent recruitment into the lesions, where they adopt an SMC-like phenotype, whereas neutralizing SDF-1 markedly reduced the neointimal area and the relative content of SMC but not macrophages.8 Thus, SDF-1 plays an instrumental role in neointima formation after injury in apoE–/– mice, attributable to a recruitment of circulating SMC progenitors. Notably, the extent of SDF-1 expression and concomitant recruitment of bone marrow-derived progenitor cells appeared to correlate with the degree of arterial trauma, ie, it was prominently detectable after wire injury but not after cuff placement or ligation.104
After arterial wire injury, SDF-1 is highly expressed in medial SMC and only later in a subset of neointimal SMC.8,104 This is compatible with the concept that resident medial SMC initially establish SDF-1 expression, migrate into the intima, and constitute a subpopulation of SDF-1-producing neointimal SMC. Known to share phenotypic characteristics with stromal cells,105 lesional SMC may provide a niche for immigrating progenitor cells by secreting SDF-1 and/or other factors. Although SDF-1 expression has not been detected in blood cells,106 it cannot be excluded that progenitor cells recruited to neointimal lesions may serve as an alternative source of SDF-1 when adopting an SMC phenotype. Because increased proteoglycan synthesis after arterial injury may add to the neointimal extracellular matrix,107 SDF-1 may be released into the circulation early after endothelial denudation, but may be bound to proteoglycans in the developing neointima, shifting its contribution from mobilization toward recruitment of progenitor cells. Beyond the initial arrest of progenitor cells, which appears to be triggered by immobilized SDF-1 in concert with activated platelets adherent at the injury site (C. Weber et al, unpublished data, 2004; see Figure 2), local SDF-1 may affect the neointimal SMC differentiation and architecture, contributing to arterial remodeling. Experiments using mice with bone marrow deficient in CXCR4– /– or SMC-specific promoters will help to clarify the role of the SDF-1/CXCR4 axis in neointimal recruitment and differentiation of SMC progenitors.
Interestingly, reduced SDF-1 plasma levels are associated with symptomatic coronary artery disease, suggesting an anti-inflammatory role for SDF-1 in stabilizing the phenotype of native atherosclerotic plaques.108 It is conceivable that the expression of SDF-1 in native lesions may regulate plaque composition by supporting a chronic influx of SMC progenitors at low levels. In apoE–/– mice, injections of bone marrow-derived progenitor cells, which also respond to SDF-1, retarded the development of primary atherosclerotic lesions.109 In contrast to its adverse effects in neointima formation, SDF-1 may thus attenuate the inflammatory progression and rather promote the stabilization of native atherosclerotic lesions.
It has been shown that neointimal SMC, which become luminally exposed after endothelial denudation injury, display a pro-inflammatory phenotype with increased expression of chemokines, thus supporting enhanced recruitment of monocytes and T cells and forming a pseudo-endothelium.110 Namely, transmembrane fractalkine and immobilized KC triggered the arrest of monocytes, whereas surface-bound SDF-1 was involved in the arrest of activated T cells but not of monocytes (Figure 2). Similarly, increased expression of RANTES by neointimal SMC (C. Weber et al, unpublished data, 2004) may provide an additional explanation for the inhibition of neointima formation after arterial injury in apoE–/– mice.64 These data extend and substantiate the functional specialization of chemokines by including those expressed on lesional SMC.
|
Role of Chemokines in Endothelial Recovery After Arterial Injury and Angiogenesis |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
Recent evidence further indicates that modalities that accelerate the re-endothelialization of vascular lesions can reduce neointima formation, eg, after vascular injury. Among the options described to date, gene transfer of vascular endothelial growth factor and treatment with statins or troglitazone have been found to improve endothelial recovery involving progenitor cells and thereby to decrease in-stent restenosis or neointima formation after denudation injury.111–114 The intravenous transfusion with endothelial progenitor cells (EPC) or spleen-derived mononuclear cells has been directly demonstrated to enhance re-endothelialization and to decrease neointima formation after vascular injury, however, only in splenectomized mice without atherosclerosis.115 Findings that EPC exhibit a migratory response to SDF-1
,116,117 which may be involved in their lesional recruitment, make it less conceivable that this mechanism would contribute to limiting neointima formation after denudation in the context of atherosclerosis, because SDF-1 is upregulated and blocking SDF-1 markedly inhibits neointima formation after arterial injury in atherosclerotic mice.8 Nevertheless, neovascularization induced by SDF-1 injection or gene transfer and associated with EPC recruitment in models of myocardial regeneration116–118 should be a focus of further investigation (Figure 2). A similar conundrum is exposed by a recent report that the intra-arterial application of bone marrow monocyte lineage CD34– CD14+ cells resulted in their adhesion to injured endothelium after activation with MCP-1 by gene transfer in vivo or by pretreatment in vitro, thereby accelerating re-endothelialization and reducing neointima formation.119 Notably, peripheral blood monocytes did not exhibit marked MCP-1-dependent adhesion or progenitor function, which is in contrast to previous reports but in line with findings on cytokine-activated endothelium. It can be assumed that these findings are rather limited to nonatherosclerotic injury repair, because transplantation of MCP-1-expressing cells or gene transfer of MCP-1 clearly exacerbates atherosclerosis in susceptible models. Similarly, local injection of MCP-1 used to increase collateral formation after arterial occlusion via CCR2-mediated perivascular recruitment of monocytes, induced systemic, ie, aortic plaque progression in apoE–/– mice.120,121
In another interesting contrast between native atherogenesis and vascular injury, we have recently found that blockade of KC inhibits the recruitment of monocytes on early atherosclerotic endothelium46 but enhances neointima formation after injury, caused by effects on endothelial recovery.122 This supports a hypothesis that restenosis may partly result from impaired re-endothelization. ELR CXC chemokines, especially IL-8, have been implicated in angiogenesis caused by activation of CXCR2 on EC or their progenitors38,39 and also by displacing growth factors from endothelial proteoglycans. The effects of blocking KC38 may also be related to interference with similar mechanisms and are not only attributable to direct effects on EPC. Endothelial migration and wound healing after scratch injury in vitro could be delayed by blocking either KC or CXCR2 and was promoted by addition of exogenous KC.122 In human atherectomy tissue of native coronary lesions, IL-8 has been identified as an important mediator of angiogenesis and may thereby promote plaque formation.123 Understanding and controlling the delicate balance in the ambivalent effects of chemokines on endothelial recovery and neovascularization as crucial features of plaque formation may hold the key to a successful therapeutic targeting.
|
Conclusions and Perspectives: Toward Therapeutic Targeting of Chemokines |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
In a synopsis, it becomes evident that the previously prevailing picture of an apparent functional redundancy of chemokines in atherogenic recruitment has to be abandoned in favor of a highly elaborate specialization and cooperation of multiple chemokines in distinct steps of the recruitment process for different mononuclear subsets and precursors of other vascular cell types. In addition, this may involve cytokines with chemokine-like functions, such as MIF, which may serve a closely related purpose. It should be noted that remarkable differences in the presentation and functional involvement of chemokines in mononuclear cell recruitment have been observed between native atherogenesis and neointima formation after injury. The framework for such a highly elaborated specialization is illustrated in Figures 1 and 2
. It cannot be excluded, however, that changes in monocyte infiltration after interference with chemokine receptors may also be caused by an altered equilibrium between influx, proliferation, and apoptosis or survival rather than solely attributable to direct effects on recruitment. This warrants studies into the effects of chemokines on vascular cell homeostasis beyond the recruitment process and may be addressed by experiments using monoclonal antibodies and conditional or inducible knockout models after manifest plaques with significant monocyte infiltration have formed. In addition, this could be directed toward achieving a regression of complicated lesions. The differences in the contribution of certain chemokines, eg, SDF-1 or KC, to neointimal hyperplasia after arterial injury versus progression of native atherosclerotic plaques could be further elaborated or corroborated by the long-term inhibition of these candidates in an atherosclerosis model simultaneously undergoing arterial injury.
Concerning the use of chemokines as therapeutic targets, various chemokine receptor antagonists have been developed that prove to be effective in animal models.48,64 As opposed to targeting other cytokines expressed in atherosclerotic plaque (eg, interferon-, tumor necrosis factor-, or interleukins4,124), which may exert an even more complex and pleiotropic spectrum of actions than chemokines including effects on T cell and monocyte differentiation, chemokine, and protease induction itself, the therapeutic inhibition of specific chemokine receptor functions may harbor the advantage of higher selectivity. However, clinical studies on the effectiveness and safety of such antagonists in the treatment and prevention of human atherosclerosis have been hampered by a lack of suitable surrogate markers for the disease in humans, which could initially substitute for hard end points such as myocardial infarction or death. This may be accomplished by developing advanced and molecular imaging techniques or disease-specific plasma biomarkers. Thus, it is not surprising that current clinical trials evaluating the efficacy of antagonist or antibodies, eg, against CCR1, CCR2, CX3CR1, or CXCR4, are mainly restricted to rheumatoid arthritis, which avoids many of these difficulties. An improved identification of patients susceptible to treatment could help to minimize potential side effects of a systemic application. Alternatively, such problems may be alleviated by identification of marker molecules enabling therapeutic targeting specific for atherosclerotic or unstable lesions. Taking these caveats into consideration, the prevention of restenosis after arterial injury or stent implantation may be a more appropriate application for assessing the efficacy of chemokine antagonists, because it may allow the use of drug-eluting stents for locally confined delivery. Similarly, other strategies for interfering with chemokine activity or expression, such as transfer of viral orthologs, inhibitors of signaling, transcription factor decoys, antisense oligonucleotides, or siRNA, may be facilitated by site-directed applications. Studies using polymer-coated stents for local delivery of chemokine antagonists are underway to assess the feasibility of this approach. It will be exciting to see these issues addressed and resolved by future research.
Received June 7, 2004; accepted August 3, 2004.
|
References |
|---|
|
TopAbstractIntroductionChemokine Expression in...Genetic Deletion of Chemokines...Functional Specialization of...Importance of Platelet...Different Functions of MCP...MIF as a Cytokine...Crucial Role of SDF-1{alpha}...Role of Chemokines in...Conclusions and Perspectives:...References |
|---|
1. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.[CrossRef][Medline] [Order article via Infotrieve]
2. Poole JC, Florey HW. Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. J Pathol Bacteriol. 1958; 75: 245–251.[CrossRef][Medline] [Order article via Infotrieve]
3. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002; 8: 1211–1217.[CrossRef][Medline] [Order article via Infotrieve]
4. Sheikine Y, Hansson G. Chemokines and atherosclerosis. Ann Med. 2004; 36: 98–118.
5. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21: 1876–1890.
6. Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res. 1998; 37: 799–810.
7. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002; 8: 403–409.[CrossRef][Medline] [Order article via Infotrieve]
8. Schober A, Knarren S, Lietz M, Lin E, Weber C. Crucial role of stromal cell-derived factor-1 in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation. 2003; 108: 2491–2497.
9. Weber C. Novel mechanistic concepts for the control of leukocyte transmigration; specialization of integrins, chemokines and junctional molecules. J Mol Med. 2003; 81: 4–19.[Medline] [Order article via Infotrieve]
10. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88: 1121–1127.
11. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Goldberg IJ, Steinberg D, Witztum JL. Expression of monocyte chemoattractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 1991; 88: 5252–5256.
12. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, Prusty S, Valente AJ, Schwartz CJ, Sonenshein GE. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acid Sci U S A. 1992; 89: 6953–6957.
13. Taubmann MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res. 1992; 70: 314–325.
14. Reape TJ, Rayner K, Manning CD, Gee AN, Barnette MS, Burnand KG, Groot PH. Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques. Am J Pathol. 1999; 154: 365–374.
15. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis. 1999; 147: 213–225.[CrossRef][Medline] [Order article via Infotrieve]
16. Greaves DR, Häkkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM, Senaratne J, Green FR, Tyson K, Boyle J, Shanahan C, Weissberg PL, Gordon S, Ylä-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001; 21: 923–929.
17. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb. 1994; 1: S10–13.
18. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant. 1996; 15: 1194–1199.[Medline] [Order article via Infotrieve]
19. Haque N, Zhang X, French D, Li J, Poon M, Fallon JT, Gabel B, Taubmann MB, Koschinsky M, Harpel PC. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation. 2000; 102: 786–792.
20. Haley KJ, Lilly CM, Yang JH, Feng Y, Kennedy SP, Turi TG, Thompson JF, Sukhova GH, Libby P, Lee RT. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation. 2000; 102: 2185–2189.
21. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A. Interleukin-8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem. 1996; 271: 8837–8842.
22. Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res. 2000; 21: 129–137.[CrossRef][Medline] [Order article via Infotrieve]
23. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, Luster AD. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 1999; 104: 1041–1050.[Medline] [Order article via Infotrieve]
24. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res. 2000; 86: 131–138.
25. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003; 111: 333–340.[CrossRef][Medline] [Order article via Infotrieve]
26. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation. 2003; 108: 2498–2504.
27. Minami M, Kume N, Shimaoka T, Kataoka H, Hayashida K, Akiyama Y, Nagata I, Ando K, Nobuyoshi M, Hanyuu M, Komeda M, Yonehara S, Kita T. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001; 21: 1796–1800.
28. Wuttge DM, Zhou X, Sheikine Y, Wagsater D, Stemme V, Hedin U, Stemme S, Hansson GK, Sirsjo A. CXCL16/SR-PSOX is an interferon- -regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2004; 24: 750–755.
29. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2: 275–281.[CrossRef][Medline] [Order article via Infotrieve]
30. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2–/– mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 3954: 894–897.
31. Dawson TC, Kuziel WA, Osahar TA, Maeda N. Abesence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999; 143: 205–211.[CrossRef][Medline] [Order article via Infotrieve]
32. Guo J, Van Eck M, Twisk J, Maeda N, Benson GM, Groot PH, Van Berkel TJ. Transplantation of monocyte CC-chemokine receptor 2-deficient bone marrow into ApoE3-Leiden mice inhibits atherogenesis. Arterioscler Thromb Vasc Biol. 2003; 23: 447–453.
33. Boisvert WA, Santiago R, Curtiss LK, Terkeltraub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998; 101: 353–363.[Medline] [Order article via Infotrieve]
34. Moser B, Barella L, Mattei S, Schumacher C, Boulay F, Colombo MP, Baggiolini M. Expression of transcripts for two interleukin 8 receptors in human phagocytes, lymphocytes and melanoma cells. Biochem J. 1993; 294: 285–292.
35. Chuntharapai A, Lee J, Hebert CA, Kim KJ. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol. 1994; 153: 5682–5688.[Abstract]
36. Lundahl J, Skold CM, Hallden G, Hallgren M, Eklund A. Monocyte and neutrophil adhesion to matrix proteins is selectively enhanced in the presence of inflammatory mediators. Scand J Immunol. 1996; 44: 143–149.[CrossRef][Medline] [Order article via Infotrieve]
37. Schwartz D, Andalibi A, Chaverri-Almada L, Berliner JA, Kirchgessner T, Fang ZT, Tekamp-Olson P, Lusis AJ, Gallegos C, Fogelman AM et al. Role of GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest. 1994; 94: 1968–1973.
38. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992; 258: 1798–1781.
39. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM. The CXC chemokine receptor 2, CXCR2, Is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol. 2000; 165: 5269–5277.
40. Veillard NR, Lu B, Pelli G, Kwak B, Charo I, Grerard C, Mach F. Crucial role for both chemokines receptors CCR2 and CXCR3 in atherogenesis. Eur Heart J. 2003; 24: A337.
41. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z. Decreased atherosclerotic lesion formation in CXCR1/apolipoprotein E double knockout mice. Circulation. 2003; 107: 1009–1016.
42. Kuziel WA, Dawson TC, Quinones M, Garavito E, Chenaux G, Ahuja SS, Reddick RL, Maeda N. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis. 2003; 167: 25–32.[CrossRef][Medline] [Order article via Infotrieve]
43. Weber KSC, von Hundelshausen P, Weber PC, Clark-Lewis I, Weber C. Differential chemokine immobilization and hierarchical involvement of their receptors in monocyte arrest and transmigration on inflammatory endothelium. Eur J Immunol. 1999; 29: 700–712.[CrossRef][Medline] [Order article via Infotrieve]
44. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr., Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999; 398: 718–723.[CrossRef][Medline] [Order article via Infotrieve]
45. Cinamon G, Shinder V, Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol. 2001; 2: 515–522.[CrossRef][Medline] [Order article via Infotrieve]
46. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest. 2001; 108: 1307–1314.[CrossRef][Medline] [Order article via Infotrieve]
47. Rollins JB. Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease. J Clin Invest. 2001; 108: 1269–1271.[CrossRef][Medline] [Order article via Infotrieve]
48. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida KI, Takeshita A. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout Mice. Circulation. 2001; 103: 2096–2101.
49. Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis J, Moser B. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol. 1998; 28: 961–972.[CrossRef][Medline] [Order article via Infotrieve]
50. Ostermann G, Weber KSC, Zernecke A, Schröder A, Weber C. JAM-1 is a ligand of the ß2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nature Immunol. 2002; 3: 151–158.[CrossRef][Medline] [Order article via Infotrieve]
51. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997; 385: 640–644.[CrossRef][Medline] [Order article via Infotrieve]
52. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998; 188: 1413–1419.
53. Zernecke A, Weber KS, Erwig LP, Kluth DC, Schröppel D, Rees AJ, Weber C. Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXCR2 in infiltration during nephrotoxic. J Immunol. 2001; 166: 5755–5762.
54. Tsou CL, Haskell CA, Charo LF. Tumor necrosis factor--converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem. 2001; 276: 44622–44626.
55. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW. Tumor necrosis factor--converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 2001; 276: 37993–38001.
56. Schäfer A, Schulz C, Eigenthaler M, Fraccarollo D, Kobsar A, Gawaz M, Ertl G, Walter U, Bauersachs J. Novel role of the membrane bound chemokine fractalkine in platelet activation and adhesion. Blood. 2003; 103: 407–412.
57. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B, Schuster B, Kallen KJ, Saftig P, Rose-John S, Ludwig A. The transmembrane CXC-chemokine ligand 16 is induced by IFN- and TNF- and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol. 2004; 172: 6362–6372.
58. Shimaoka T, Nakayama T, Fukumoto N, Kume N, Takahashi S, Yamaguchi J, Minami M, Hayashida K, Kita T, Ohsumi J, Yoshie O, Yonehara. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol. 2004; 75: 267–274.
59. Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem. 2004; 279: 3188–3196.
60. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol. 2004; 172: 3678–3685.
61. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000; 177: 204–216.[CrossRef][Medline] [Order article via Infotrieve]
62. Gröne HJ, Weber C, Weber KS, Gröne EF, Rabelink T, Klier CM, Wells TN, Proudfoot AE, Schlöndorff D, Nelson PJ. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. 1999; 13: 1371–1383.
63. von Hundelshausen P, Weber KSC, Huo Y, Proudfoot AEI, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. 2001; 103: 1772–1777.
64. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002; 106: 1523–1529.
65. Huo Y, Schober A, Forlow B, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Med. 2003; 9: 61–67.[CrossRef][Medline] [Order article via Infotrieve]
66. Mack M, Pfirstinger J, Weber C, Weber KSC, Nelson PJ, Rupp T, Maletz K, Brühl H, Schlöndorff D. Chondroitin sulfate A released from platelets blocks RANTES presentation and RANTES-dependent firm adhesion of leukocytes. Eur J Immunol. 2002; 32: 1012–1020.[CrossRef][Medline] [Order article via Infotrieve]
67. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2004; 94: 253–261.
68. Weber C, Weber KSC, Klier C, Gu H, Horuk R, Wank R, Nelson PJ. Specialized roles of the chemokine receptors CCR1 and CCR5 in recruitment of monocytes and Th1-like/CD45RO+T cells. Blood. 2001; 97: 1144–1146.
69. Baltus T, Weber KSC, Johnson Z, Proudfoot AEI, Weber C. Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood. 2003; 102: 1985–1988.
70. Ghaddar HB, Cortes J, Salomaa V, Kark JD, Davic CE, Folsom AR, Heiss G, Stinson V, Wu KK. Correlation of specific platelet activation markers with carotid arterial wall thickness. Thromb Haemost. 1995; 74: 943–948.[Medline] [Order article via Infotrieve]
71. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giani S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003; 197: 1537–1549.
72. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation. 2003; 10: 335–350.[CrossRef][Medline] [Order article via Infotrieve]
73. Gear AR, Suttitanamongkol S, Viisoreanu D, Polanowska-Grabowska RK, Raha S, Camerini D. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood. 2001; 97: 937–945.
74. Han KH, Tangirala RK, Green SR, Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol. 1998; 18: 1983–1991.
75. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, Inoue N, Hirata K, Matsukawa A, Morishita R, Kaneda Y, Yokoyama M. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002; 22: 115–120.
76. Schober A, Lin EA, von Hundelshausen P, Knarren S, Kuziel WA, Weber C. The crucial role of CCL2/CCR2 axis in neointimal hyperplasia after arterial injury involves early monocyte recruitment and CCL2 presentation on platelets in hyperlipidemic mice. Z Kardiol. 2004; 93 S3: III/A405.
77. Mori E, Komori K, Yamaoka T, Tanii M, Kataoka C, Takeshita A, Usui M, Egashira K, Sugimachi K. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation. 2002; 105: 2905–2910.
78. Horvath C, Welt FG, Nedelmann M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res. 2002; 90: 488–494.
79. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K, Inoue S, Katoh M, Ichiki T, Takeshita A. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res. 2002; 90: 1167–1172.
80. Roque M, Kim WJ, Gazdoin M, Malik A, Reis ED, Fallon JT, Badimo JJ, Charo IF, Taubman MB. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol. 2002; 22: 554–559.
81. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S. Anti-monocyte chemoattractant proetin-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. 1999; 84: 306–314.
82. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggioloni M, Wells TN. Functional expression of CCR1, CCR3, CCR4 and CXCR4 chemokine receptors on human platelets. Blood. 2000; 96: 4046–4054.
83. George JN, Onofre AR. Human platelet surface binding of endogenous secreted factor VIII-von Willebrand factor and platelet factor 4. Blood. 1982; 59: 194–197.
84. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, Wells TN. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemestry. 1999; 38: 12959–12968.
85. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, Weber C. Stabilization of ahterosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation. 2004; 109: 380–385.
86. Degryse B, de Virgilio M. The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett. 2003; 9: 11–17.
87. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993; 365: 756–759.[CrossRef][Medline] [Order article via Infotrieve]
88. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003; 3: 791–800.[CrossRef][Medline] [Order article via Infotrieve]
89. Sun H, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A. 1996; 93: 5191–5196.
90. Hoover DM, Boulegue C, Yang D, Oppenheim JJ, Tucker K, Lu W, Lubkowski J. The structure of human macrophage inflammatory protein-3 /CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human ß-defensis. J Biol Chem. 2002; 277: 37647–37654.
91. Hermanowski-Vosatka A, Mundt SS, Ayala JM, Goyal S, Hanlon WA, Czerwinski RM, Wright SD, Whitman CP. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry. 1999; 38: 12841–12849.[CrossRef][Medline] [Order article via Infotrieve]
92. Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer. 2003; 107: 22–29.[CrossRef][Medline] [Order article via Infotrieve]
93. Lan HY, Bacher M, Yang N, Mu W, Nikolic-Paterson DJ, Metz C, Meinhardt A, Bucala R, Atkins RC. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med. 1997; 185: 1455–1465.
94. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, Kleemann R, Bernhagen J, Ihling C. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation. 2002; 105: 1561–1566.
95. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, Bucala R, Lau CP, Lau HY. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res. 2000; 87: 1202–1208.
96. Chen Z, Sakuma M, Zago AC, Zhang X, Shi C, Leng L, Mizue Y, Bucala R, Simon DI. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol. 2004; 4: 709–714.
97. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, Zhang Y, Satoskar AR, David JR, Metz CN, Bucala R, Fang K, Simon DI, Chapman HA, Libby P, Shi GP. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2004; 109: 3149–3153.
98. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999; 283: 845–848.
99. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, Magerus A, Caruz A, Fujii N, Nagler A, Lahav M, Szyper-Kravitz M, Zipori D, Lapidot T. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000; 106: 1331–1339.[Medline] [Order article via Infotrieve]
100. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002; 30: 973–981.[CrossRef][Medline] [Order article via Infotrieve]
101. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nischikawa S, Kishimoto T, Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestenial tract. Nature. 1998; 393: 591–594.[CrossRef][Medline] [Order article via Infotrieve]
102. Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res. 2001; 38: 113–119.[CrossRef][Medline] [Order article via Infotrieve]
103. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation. 2002; 106: 1199–1204.
104. Tanaka K, Sata M, Hirata Y, Nagai R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ Res. 2003; 93: 783–790.
105. Galmiche MC, Koteliansky VE, Briere J, Herve P, Charbord P. Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood. 1993; 82: 66–76.
106. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science. 1993; 261: 600–603.
107. Strauss BH, Shisholm RJ, Keely FW, Gotlieb AI, Logan RA, Armstrong PW. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res. 1994; 75: 650–658.
108. Damas JK, Waehre T, Yndestadt A, Ueland T, Muller F, Eiken HG, Holm AM, Halvorsen B, Froland SS, Gullestad L, Aukrust P. Stromal cell-derived factor-1 in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation. 2002; 106: 36–42.
109. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003; 108: 457–463.
110. Zeiffer U, Schober A, Lietz M, Erl W, Yan ZQ, Weber C. Neointimal smooth muscle cells support increased monocyte arrest in flow by constitutively enhanced expression of P-selectin and chemonkines. Circ Res. 2004; 94: 776–784.
111. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hyashi S, Silver M, Li T, Isner JM, Asahara T. Endothelial progenitor growth factor gene transfer for vascular regeneration. Circulation. 2002; 105: 732–738.
112. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002; 105: 3017–3024.
113. Hedmann M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, Vanninen E, Mussalo H, Kauppila E, Simula S, Narvanen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Ylä-Herttuala S. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003; 107: 2677–2683.
114. Hannan KM, Dilley RJ, De Dios ST, Little PJ. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler Thromb Vasc Biol. 2003; 23: 762–768.
115. Werner N, Junk S, Laufs Uwalenta K, Bohm M, Nickenig G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003; 93: e17–e24.
116. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003; 107: 1322–1328.
117. Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J, Schmitt J, Vogl TJ, Martin H, Schächinger V, Dimmeler S, Zeiher AM. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation. 2003; 108: 2212–2218.
118. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S, Sata M, Ichiki T, Takeshita A, Egashira K. Gene transfer of stromal cell-derived factor-1 enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation. 2004; 109: 2454–2461.
119. Fujiyama S, Amaon K, Uehira K, Yoshida M, Nishiwaki Y, Nozawa Y, Jin D, Takai S, Miyazaki M, Egashira K, Imada T, Iwasaka T, Matubara H. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate re-endothelialization as endothelial progenitor cells. Circ Res. 2003; 93: 980–989.
120. Van Royen N, Hoefer I, Bottinger M, Hua J, Grundmann S, Voskuil M, Bode C, Schaper W, Buschmann I, Piek JJ. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocyte CD11b expression, neointiomal formation, and plaque progression. Circ Res. 2003; 92: 218–225.
121. Heil M, Ziegelhoeffer T, Wagner S, Fernandez B, Helisch A, Martin S, Tribulova S, Kuziel WA, Bachmann G, Schaper W. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res. 2004; 94: 671–677.
122. Liehn EA, Schober A, Weber C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol., in press.
123. Simonini A, Moscucci M, Muller DW, Bates ER, Pagani FD, Burdick MD, Strieter RM. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation. 2000; 101: 1519–1526.
124. von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003; 55: 133–166.
This article has been cited by other articles:
 |
|
 |
|
  F. L.H. Muntinghe, M. Verduijn, M. W. Zuurman, D. C. Grootendorst, J. J. Carrero, A. R. Qureshi, K. Luttropp, L. Nordfors, B. Lindholm, V. Brandenburg, et al. CCR5 Deletion Protects Against Inflammation-Associated Mortality in Dialysis Patients J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1641 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Tziakas, G. K. Chalikias, I. K. Tentes, D. Stakos, S. V. Chatzikyriakou, K. Mitrousi, A. X. Kortsaris, J. C. Kaski, and H. Boudoulas Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome Eur. Heart J., November 2, 2008; 29(22): 2713 - 2722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zernecke, E. Shagdarsuren, and C. Weber Chemokines in Atherosclerosis: An Update Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 1897 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schober Chemokines in Vascular Dysfunction and Remodeling Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 1950 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weber, S. Kraemer, M. Drechsler, H. Lue, R. R. Koenen, A. Kapurniotu, A. Zernecke, and J. Bernhagen Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment PNAS, October 21, 2008; 105(42): 16278 - 16283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gustin, M. Van Steenbrugge, and M. Raes LPA modulates monocyte migration directly and via LPA-stimulated endothelial cells Am J Physiol Cell Physiol, October 1, 2008; 295(4): C905 - C914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Ali, C. A. Bursill, G. Douglas, E. McNeill, M. Papaspyridonos, A. L. Tatham, J. K. Bendall, A. M. Akhtar, N. J. Alp, D. R. Greaves, et al. CCR2-Mediated Antiinflammatory Effects of Endothelial Tetrahydrobiopterin Inhibit Vascular Injury-Induced Accelerated Atherosclerosis Circulation, September 30, 2008; 118(14_suppl_1): S71 - S77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gouwy, S. Struyf, S. Noppen, E. Schutyser, J.-Y. Springael, M. Parmentier, P. Proost, and J. Van Damme Synergy between Coproduced CC and CXC Chemokines in Monocyte Chemotaxis through Receptor-Mediated Events Mol. Pharmacol., August 1, 2008; 74(2): 485 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J.A. van Wanrooij, P. de Vos, M. G. Bixel, D. Vestweber, T. J.C. van Berkel, and J. Kuiper Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice Cardiovasc Res, June 1, 2008; 78(3): 590 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zernecke, J. Bernhagen, and C. Weber Macrophage Migration Inhibitory Factor in Cardiovascular Disease Circulation, March 25, 2008; 117(12): 1594 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Montecucco, F. Burger, F. Mach, and S. Steffens CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1145 - H1155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J.A. van Wanrooij, S. C.A. de Jager, T. van Es, P. de Vos, H. L. Birch, D. A. Owen, R. J. Watson, E. A.L. Biessen, G. A. Chapman, T. J.C. van Berkel, et al. CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 251 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zernecke, I. Bot, Y. Djalali-Talab, E. Shagdarsuren, K. Bidzhekov, S. Meiler, R. Krohn, A. Schober, M. Sperandio, O. Soehnlein, et al. Protective Role of CXC Receptor 4/CXC Ligand 12 Unveils the Importance of Neutrophils in Atherosclerosis Circ. Res., February 1, 2008; 102(2): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shao, Y. Shen, H. Liu, G. Dong, J. Qiang, and H. Jing Simvastatin Suppresses Lung Inflammatory Response in a Rat Cardiopulmonary Bypass Model Ann. Thorac. Surg., December 1, 2007; 84(6): 2011 - 2018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Karshovska, A. Zernecke, G. Sevilmis, A. Millet, M. Hristov, C. D. Cohen, H. Schmid, F. Krotz, H.-Y. Sohn, V. Klauss, et al. Expression of HIF-1{alpha} in Injured Arteries Controls SDF-1{alpha} Mediated Neointima Formation in Apolipoprotein E Deficient Mice Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2540 - 2547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. N. A. Nabah, M. Losada, R. Estelles, T. Mateo, C. Company, L. Piqueras, C. Lopez-Gines, H. Sarau, J. Cortijo, E. J. Morcillo, et al. CXCR2 Blockade Impairs Angiotensin II Induced CC Chemokine Synthesis and Mononuclear Leukocyte Infiltration Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2370 - 2376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Gruen, M. Hao, D. W. Piston, and A. H. Hasty Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1481 - C1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.O. Kraaijeveld, S.C.A. de Jager, W.J. de Jager, B.J. Prakken, S.R. McColl, I. Haspels, H. Putter, T.J.C. van Berkel, L. Nagelkerken, J.W. Jukema, et al. CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms Circulation, October 23, 2007; 116(17): 1931 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Krohn, U. Raffetseder, I. Bot, A. Zernecke, E. Shagdarsuren, E. A. Liehn, P. J. van Santbrink, P. J. Nelson, E. A. Biessen, P. R. Mertens, et al. Y-Box Binding Protein-1 Controls CC Chemokine Ligand-5 (CCL5) Expression in Smooth Muscle Cells and Contributes to Neointima Formation in Atherosclerosis-Prone Mice Circulation, October 16, 2007; 116(16): 1812 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Gleissner, N. Leitinger, and K. Ley Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in Atherosclerosis Hypertension, August 1, 2007; 50(2): 276 - 283. [Full Text] [PDF]
|
|
|
|
|
|
E. Cavusoglu, C. Eng, V. Chopra, L. T. Clark, D. J. Pinsky, and J. D. Marmur Low Plasma RANTES Levels Are an Independent Predictor of Cardiac Mortality in Patients Referred for Coronary Angiography Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 929 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. M. Shah, K. Morimura, and F. J. Gonzalez Expression of peroxisome proliferator-activated receptor-{gamma} in macrophage suppresses experimentally induced colitis Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G657 - G666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simionescu Implications of Early Structural-Functional Changes in the Endothelium for Vascular Disease Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 266 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Braunersreuther, A. Zernecke, C. Arnaud, E. A. Liehn, S. Steffens, E. Shagdarsuren, K. Bidzhekov, F. Burger, G. Pelli, B. Luckow, et al. Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 373 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. I. Bonta, C. M. van Tiel, M. Vos, T. W.H. Pols, J. V. van Thienen, V. Ferreira, E. K. Arkenbout, J. Seppen, C. A. Spek, T. van der Poll, et al. Nuclear Receptors Nur77, Nurr1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2288 - 2288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Henke, C. G. Pearce, D. M. Moaveni, A. J. Moore, E. M. Lynch, C. Longo, M. Varma, N. A. Dewyer, K. B. Deatrick, G. R. Upchurch Jr, et al. Targeted Deletion of CCR2 Impairs Deep Vein Thombosis Resolution in a Mouse Model. J. Immunol., September 1, 2006; 177(5): 3388 - 3397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mieno, B. Ramlawi, M. Boodhwani, R. T. Clements, K. Minamimura, T. Maki, S.-H. Xu, C. Bianchi, J. Li, and F. W. Sellke Role of Stromal-Derived Factor-1{alpha} in the Induction of Circulating CD34+CXCR4+ Progenitor Cells After Cardiac Surgery. Circulation, July 4, 2006; 114(1 Suppl): 186 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Garton, P. J. Gough, and E. W. Raines Emerging roles for ectodomain shedding in the regulation of inflammatory responses J. Leukoc. Biol., June 1, 2006; 79(6): 1105 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zernecke, E. A. Liehn, J.-L. Gao, W. A. Kuziel, P. M. Murphy, and C. Weber Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10 Blood, June 1, 2006; 107(11): 4240 - 4243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bidzhekov, A. Zernecke, and C. Weber MCP-1 Induces a Novel Transcription Factor With Proapoptotic Activity Circ. Res., May 12, 2006; 98(9): 1107 - 1109. [Full Text] [PDF]
|
|
|
|
|
|
T. Mateo, Y. Naim Abu Nabah, M. Abu Taha, M. Mata, M. Cerda-Nicolas, A. E. I. Proudfoot, R. A. K. Stahl, A. C. Issekutz, J. Cortijo, E. J. Morcillo, et al. Angiotensin II-Induced Mononuclear Leukocyte Interactions with Arteriolar and Venular Endothelium Are Mediated by the Release of Different CC Chemokines J. Immunol., May 1, 2006; 176(9): 5577 - 5586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. W. Raines Antigen-Independent Targeting of Long-Lived CD4+ Cytolytic T Effector Cells to Lesions of Atherosclerosis Circ. Res., March 3, 2006; 98(4): 434 - 436. [Full Text] [PDF]
|
|
|
|
|
|
C.-N. Chen, S.-F. Chang, P.-L. Lee, K. Chang, L.-J. Chen, S. Usami, S. Chien, and J.-J. Chiu Neutrophils, lymphocytes, and monocytes exhibit diverse behaviors in transendothelial and subendothelial migrations under coculture with smooth muscle cells in disturbed flow Blood, March 1, 2006; 107(5): 1933 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Norata, G. Tibolla, P. M. Seccomandi, A. Poletti, and A. L. Catapano Dihydrotestosterone Decreases Tumor Necrosis Factor-{alpha} and Lipopolysaccharide-Induced Inflammatory Response in Human Endothelial Cells J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 546 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zernecke, E. A. Liehn, L. Fraemohs, P. von Hundelshausen, R. R. Koenen, M. Corada, E. Dejana, and C. Weber Importance of Junctional Adhesion Molecule-A for Neointimal Lesion Formation and Infiltration in Atherosclerosis-Prone Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): e10 - e13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Rothenbacher, S. Muller-Scholze, C. Herder, W. Koenig, and H. Kolb Differential Expression of Chemokines, Risk of Stable Coronary Heart Disease, and Correlation with Established Cardiovascular Risk Markers Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 194 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Weber Killing Two Birds With One Stone: Targeting Chemokine Receptors in Atherosclerosis and HIV Infection Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2448 - 2450. [Full Text] [PDF]
|
|
|
|
|
|
E. Henrichot, C. E. Juge-Aubry, A. Pernin, J.-C. Pache, V. Velebit, J.-M. Dayer, P. Meda, C. Chizzolini, and C. A. Meier Production of Chemokines by Perivascular Adipose Tissue: A Role in the Pathogenesis of Atherosclerosis? Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2594 - 2599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Smith, E. Galkina, K. Ley, and Y. Huo GRO family chemokines are specialized for monocyte arrest from flow Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1976 - H1984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. A. Ali, C. A. Bursill, Y. Hu, R. P. Choudhury, Q. Xu, D. R. Greaves, and K. M. Channon Gene Transfer of a Broad Spectrum CC-Chemokine Inhibitor Reduces Vein Graft Atherosclerosis in Apolipoprotein E-Knockout Mice Circulation, August 30, 2005; 112(9_suppl): I-235 - I-241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bernhard, A. Csordas, B. Henderson, A. Rossmann, M. Kind, and G. Wick Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules FASEB J, July 1, 2005; 19(9): 1096 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Mause, P. von Hundelshausen, A. Zernecke, R. R. Koenen, and C. Weber Platelet Microparticles: A Transcellular Delivery System for RANTES Promoting Monocyte Recruitment on Endothelium Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1512 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. W. Raines and N. Ferri Thematic Review Series: The Immune System and Atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease J. Lipid Res., June 1, 2005; 46(6): 1081 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zernecke, A. Schober, I. Bot, P. von Hundelshausen, E. A. Liehn, B. Mopps, M. Mericskay, P. Gierschik, E. A. Biessen, and C. Weber SDF-1{alpha}/CXCR4 Axis Is Instrumental in Neointimal Hyperplasia and Recruitment of Smooth Muscle Progenitor Cells Circ. Res., April 15, 2005; 96(7): 784 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Weber Platelets and Chemokines in Atherosclerosis: Partners in Crime Circ. Res., April 1, 2005; 96(6): 612 - 616. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||